We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise.
- Authors
Park, Juri; Park, Sung Woo; Yoon, Kun Ho; Kim, Sung Rae; Ahn, Kyu Jeung; Lee, Jae Hyuk; Mok, Ji Oh; Chung, Choon Hee; Han, Kyung Ah; Koh, Gwan Pyo; Kang, Jun Goo; Lee, Chang Beom; Kim, Seong Hwan; Kwon, Na Young; Kim, Doo Man
- Abstract
Aims To evaluate the efficacy and safety of evogliptin, a newly developed dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes ( T2D) inadequately controlled by diet and exercise. Materials and Methods In this randomized, double-blind, placebo-controlled, parallel-group, multicentre, phase III study, 160 patients with T2D were assigned to either evogliptin 5 mg or placebo for 24 weeks. The primary endpoint was the mean change in glycated haemoglobin ( HbA1c) from baseline to week 24. Results The mean baseline HbA1c levels were similar in the evogliptin and the placebo groups (7.20% ± 0.56% vs 7.20% ± 0.63%, respectively). At week 24, evogliptin significantly reduced HbA1c levels from baseline compared with placebo (−0.23% vs 0.05%, respectively, P < .0001). Additionally, the proportion of patients achieving HbA1c <6.5% was significantly higher in the evogliptin group than in the placebo group (33.3% vs 15.2%; P = .008). The overall incidence of adverse events, including hypoglycaemia, was similar in the 2 groups. Conclusions In this 24-week study, once-daily evogliptin monotherapy significantly improved glycaemic control and was well tolerated in patients with T2D.
- Subjects
TYPE 2 diabetes treatment; HYPOGLYCEMIC agents; GLYCOSYLATED hemoglobin; DIET; EXERCISE physiology; CD26 antigen
- Publication
Diabetes, Obesity & Metabolism, 2017, Vol 19, Issue 12, p1681
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.12987